New drugs 2003, part II.
Hussar
Daniel  A
D
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003271:Contraceptive Agents, Female / Q000627:therapeutic use; D003277:Contraceptives, Oral, Combined / Q000627:therapeutic use; D017135:Desogestrel; D017277:Drug Approval; D004338:Drug Combinations; D004358:Drug Therapy / Q000592:standards*; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005003:Ethisterone / Q000031:analogs & derivatives; D000069585:Filgrastim; D000077425:Fondaparinux; D000077267:Fulvestrant; D016179:Granulocyte Colony-Stimulating Factor / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D009644:Norgestrel / Q000031:analogs & derivatives; D010091:Oximes; D011092:Polyethylene Glycols; D011134:Polysaccharides / Q000627:therapeutic use; D011994:Recombinant Proteins; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014481:United States; D014753:Vinyl Compounds / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D010091:Oximes; D011134:Polysaccharides; D011994:Recombinant Proteins; D014753:Vinyl Compounds; D017329:Triptorelin Pamoate; D016179:Granulocyte Colony-Stimulating Factor; D000077267:Fulvestrant; C044815:etonogestrel; C455861:pegfilgrastim; D009644:Norgestrel; D011092:Polyethylene Glycols; C422802:ibritumomab tiuxetan; D004958:Estradiol; D017135:Desogestrel; D011464:Epoprostenol; D000077425:Fondaparinux; D005003:Ethisterone; D000069585:Filgrastim; C449219:norelgestromin; C427248:treprostinil